Document is current
Any future updates will be listed below
-
Authors
Subramanian, Prem S https://orcid.org/0000-0001-5824-8322
Newman, Nancy J
Moster, Mark
Wang, An-Guor
Yu-Wai-Man, Patrick
Donahue, Sean
Leroy, Bart P
Carelli, Valerio
Biousse, Valerie
Vignal-Clermont, Catherine
Sergott, Robert C
Sadun, Alfredo A
Rebolleda, Gema
Chwalisz, Bart K https://orcid.org/0000-0001-9918-1742
Banik, Rudrani
Bazin, Fabienne
Cox, Eric
Roux, Michel
Taiel, Magali
Sahel, Jose-Alain
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03293524 at ClinicalTrials.govnct03293524 at ClinicalTrials.govDocuments that mention this clinical trial
Study design and baseline characteristics for the reflect gene therapy trial ofm.11778g>A/<i>ND4</i>-LHON
https://doi.org/10.1136/bmjophth-2022-001158
Indirect Comparison of Lenadogene Nolparvovec Gene Therapy Versus Natural History in Patients with Leber Hereditary Optic Neuropathy Carrying the m.11778G>A MT-ND4 Mutation
https://doi.org/10.1007/s40123-022-00611-x
Documents that mention this clinical trial
Study design and baseline characteristics for the reflect gene therapy trial ofm.11778g>A/<i>ND4</i>-LHON
https://doi.org/10.1136/bmjophth-2022-001158
Indirect Comparison of Lenadogene Nolparvovec Gene Therapy Versus Natural History in Patients with Leber Hereditary Optic Neuropathy Carrying the m.11778G>A MT-ND4 Mutation
https://doi.org/10.1007/s40123-022-00611-x
-
Funding
Funding for this research was provided by:
GenSight Biologics
- License Information
